Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy

被引:23
作者
Qian, Da
Li, Jialu [2 ]
Huang, Mingyao [1 ,3 ]
Cui, Qiuxia [2 ]
Liu, Xiaozhen [4 ]
Sun, Kailv [3 ,5 ]
机构
[1] Soochow Univ, Changshu Hosp, Dept Burn & Plast Surg Hand Surg, Changshu 215500, Peoples R China
[2] Nanjing Univ Chinese Med, Changshu Hosp, Dept Breast Surg, Changshu 215500, Peoples R China
[3] Fujian Med Univ, Union Hosp, Dept Breast Surg, Fuzhou 350000, Peoples R China
[4] Zhejiang Prov Peoples Hosp, Hangzhou Med Coll, Peoples Hosp, Canc Ctr,Dept Breast Surg, Hangzhou, Peoples R China
[5] Soochow Univ, Changshu Hosp, Dept Breast Surg, Changshu 215500, Peoples R China
关键词
Dendritic cell; Vaccines; Breast cancer; Immune regulation; Immunotherapy; MUC1; IDENTIFICATION; COMBINATION; ANTIGEN; GROWTH; VACCINATION; RESPONSES; EXOSOMES;
D O I
10.1016/j.biopha.2023.114685
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Breast cancer (BC) is the most common cancer in women worldwide. Although substantial progress has been made in the diagnosis and treatment of breast cancer, the efficacy and side effects of traditional treatment methods are still unsatisfactory. In recent years, immunotherapy including tumor vaccine has achieved great success in the treatment of BC. Dendritic cells (DCs) are multifunctional antigen-presenting cells that play an important role in the initiation and regulation of innate and adaptive immune responses. Numerous studies have shown that DC-based treatments might have a potential effect on BC. Among them, the clinical study of DC vaccine in BC has demonstrated considerable anti-tumor effect, and some DC vaccines have entered the stage of clinical trials. In this review, we summarize the immunomodulatory effects and related mechanisms of DC vaccine in breast cancer as well as the progress of clinical trials to propose possible challenges of DC vaccines and new development directions.
引用
收藏
页数:7
相关论文
共 74 条
  • [1] Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer The Neo-PATH Phase 2 Nonrandomized Clinical Trial
    Ahn, Hee Kyung
    Sim, Sung Hoon
    Suh, Koung Jin
    Kim, Min Hwan
    Jeong, Jae Ho
    Kim, Ji-Yeon
    Lee, Dae-Won
    Ahn, Jin-Hee
    Chae, Heejung
    Lee, Kyung-Hun
    Kim, Jee Hyun
    Lee, Keun Seok
    Sohn, Joo Hyuk
    Choi, Yoon-La
    Im, Seock-Ah
    Jung, Kyung Hae
    Park, Yeon Hee
    [J]. JAMA ONCOLOGY, 2022, 8 (09) : 1271 - 1277
  • [2] Dendritic Cell Vaccine and Cancer Treatment: New Patents
    Aleixo, Andre A. R.
    Michelin, Marcia A.
    Murta, Eddie F. C.
    [J]. RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2014, 8 (01) : 26 - 29
  • [3] Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade
    Bai, Xuewei
    Zhou, Yanmei
    Yokota, Yuki
    Matsumoto, Yoshihiro
    Zhai, Bo
    Maarouf, Nader
    Hayashi, Hikaru
    Carlson, Rolf
    Zhang, Songhua
    Sousa, Aryanna
    Sun, Bei
    Ghanbari, Hossein
    Dong, Xiaoqun
    Wands, Jack R.
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [4] Dendritic cells and the control of immunity
    Banchereau, J
    Steinman, RM
    [J]. NATURE, 1998, 392 (6673) : 245 - 252
  • [5] Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine
    Basu, Amrita
    Albert, Gabriella K.
    Awshah, Sabrina
    Datta, Jashodeep
    Kodumudi, Krithika N.
    Gallen, Corey
    Beyer, Amber
    Smalley, Keiran S. M.
    Rodriguez, Paulo C.
    Duckett, Derek R.
    Forsyth, Peter A.
    Soyano, Aixa
    Koski, Gary K.
    Costa, Ricardo Lima Barros
    Han, Heather
    Soliman, Hatem
    Lee, Marie Catherine
    Kalinski, Pawel
    Czerniecki, Brian J.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01) : 108 - 125
  • [6] Beatson RE, 2010, IMMUNOTHERAPY-UK, V2, P305, DOI [10.2217/imt.10.17, 10.2217/IMT.10.17]
  • [7] Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
    Bernal-Estevez, David A.
    Ortiz Barbosa, Mauren A.
    Ortiz-Montero, Paola
    Cifuentes, Claudia
    Sanchez, Ramiro
    Parra-Lopez, Carlos A.
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [8] Runx2 in normal tissues and cancer cells: A developing story
    Blyth, Karen
    Vaillant, Francois
    Jenkins, Alma
    McDonald, Laura
    Pringle, Marie Anne
    Huser, Camille
    Stein, Torsten
    Neil, James
    Cameron, Ewan R.
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2010, 45 (02) : 117 - 123
  • [9] Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
    Brossart, P
    Heinrich, KS
    Stuhler, G
    Behnke, L
    Reichardt, VL
    Stevanovic, S
    Muhm, A
    Rammensee, HG
    Kanz, L
    Brugger, W
    [J]. BLOOD, 1999, 93 (12) : 4309 - 4317
  • [10] CD133 in Breast Cancer Cells: More than a Stem Cell Marker
    Brugnoli, Federica
    Grassilli, Silvia
    Al-Qassab, Yasamin
    Capitani, Silvano
    Bertagnolo, Valeria
    [J]. JOURNAL OF ONCOLOGY, 2019, 2019